Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Radiat Oncol
Main Authors: Ohno, Makoto, Miyakita, Yasuji, Takahashi, Masamichi, Igaki, Hiroshi, Matsushita, Yuko, Ichimura, Koichi, Narita, Yoshitaka
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852964/
https://ncbi.nlm.nih.gov/pubmed/31718669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13014-019-1389-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados